Concentra Q2 2026 earnings: Operating leverage lifts profit and cash flow

Concentra Group Holdings Parent, Inc. (NYSE: CON) reported Q2 2026 revenue of $606.0 million, up 10.0% from $550.8 million a year earlier, while diluted EPS rose to $0.51 from $0.35. Adjusted EBITDA increased 22.5% to $140.9 million, and free cash flow rose 91.6% to $121.0 million as higher earnings, liability-payment timing and lower capital expenditures supported cash generation.

Core earnings data

Revenue growth translated into faster profit growth because costs and expenses increased 6.3%, below the 10.0% increase in revenue. Operating income rose 28.5%, while net income attributable to Concentra increased 46.5%, also benefiting from lower interest expense.

Cash generation grew faster than earnings. Operating cash flow increased 53.0%, and reduced capital spending contributed to the larger increase in free cash flow.

Adjusted EBITDA and free cash flow are non-GAAP measures. EPS and net income attributable to Concentra are reported on a GAAP basis.

Business and operating performance

Concentra recorded 3.61 million patient visits during the quarter. Average daily visits increased 2.6% to 56,421, while revenue per visit rose 4.6% to $152.67. The combination of higher activity and more revenue per visit supported the quarter’s revenue growth.

The company ended June with 633 occupational health centers, compared with 628 a year earlier, after opening one de novo center during the quarter. Its onsite health clinic count increased to 415 from 406. These figures indicate measured expansion across both principal care settings, although the release did not provide separate revenue or profit results for each setting.

Operating leverage and lower capital spending magnified cash generation

Concentra’s operating margin was approximately 19.0%, up from about 16.3% in Q2 2025. Cost of services increased 6.3%, general and administrative expense rose 7.1%, and depreciation and amortization grew 4.7%—each below the rate of revenue growth. Transition services agreement fees also declined to $1.0 million from $3.5 million.

Below the operating line, interest expense fell 8.8% to $25.7 million. The combination of operating leverage and lower interest expense helped produce substantially faster growth in net income than in revenue.

The 53.0% increase in operating cash flow reflected higher net income from organic growth, acquisitions and de novo locations, as well as the timing of current-liability payments. Accounts payable and accrued liabilities contributed $49.2 million to quarterly operating cash flow, compared with $28.7 million a year earlier. Free cash flow received an additional lift from the 37.9% reduction in capital expenditures and $1.5 million of asset-sale proceeds.

Concentra finished the quarter with $158.0 million in cash and $1.57 billion in total debt. Its net leverage ratio was 2.99 times and remained in compliance with the financial covenant under its credit agreement. Financing activities used $24.7 million, including $11.0 million for approximately 0.4 million share repurchases and $8.0 million in dividend payments.

The board separately declared a quarterly cash dividend of $0.0625 per share, payable on or about August 28, 2026, to shareholders of record on August 20.

FY 2026 guidance

Concentra raised its full-year 2026 financial outlook. The release did not provide the previous guidance ranges, so the size of the increase cannot be quantified from the available information.

The leverage target is particularly relevant because the ratio stood at 2.99 times at quarter-end. Adjusted EBITDA and free cash flow guidance use non-GAAP measures.

Management outlook and leadership transition

Management attributed the quarter’s performance to Concentra’s strategy, operating model and workforce. Its stated priorities remain delivering care, creating value for customers and patients, and pursuing disciplined growth while using the company’s operating leverage.

Concentra also announced a planned leadership transition effective November 1, 2026. President and CFO Matt DiCanio will become president and CEO and join the board, while current CEO Keith Newton will become executive chairman. Robert Ortenzio will step down as chairman but remain a director. The company expects to announce its CFO succession plan before the transition takes effect.

Risks investors should watch

• Patient-volume sensitivity: Daily visits grew 2.6%, making the frequency of workplace injuries and illnesses, as well as relationships with employer customers and payors, important drivers of future revenue.
• Reimbursement and cost pressure: Changes in workers’ compensation fee schedules or reimbursement that fails to keep pace with labor and other costs could reverse some of the quarter’s margin expansion.
• Cash-flow comparability: Quarterly free cash flow benefited from liability-payment timing and lower capital expenditures. Those factors mean its 91.6% growth rate should not be attributed solely to recurring profit growth.
• Leverage requirements: Concentra carried $1.57 billion of debt and ended the quarter at 2.99 times net leverage. Sustained cash generation will be important for maintaining the company’s below-3.0-times target.
• Management succession: The CEO transition is planned, but the replacement for DiCanio in the CFO role had not yet been announced, leaving an additional leadership step to complete before November.

Summary

Concentra’s Q2 2026 revenue growth was supported by increases in both daily patient visits and revenue per visit, while costs grew more slowly and interest expense declined. That operating leverage drove faster earnings growth, and lower capital spending plus working-capital timing amplified cash generation. The main follow-up points are execution against the raised full-year guidance, maintenance of net leverage below 3.0 times and completion of the planned leadership transition.